Macquarie Group LTD Hutchmed (China) LTD Transaction History

Macquarie Group LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$35.66 - $42.94 $158,829 - $191,254	4,454 New	4,454 $163,000
Q1 2021 May 14, 2021	SELL	$27.01 - $36.8 $148,906 - $202,878	-5,513 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$27.51 - $34.36 $45,611 - $56,968	-1,658 Reduced 23.12%	5,513 $176,000
Q3 2020 Nov 13, 2020	BUY	$25.8 - $34.61 $4,824 - $6,472	187 Added 2.68%	7,171 $232,000
Q1 2020 May 15, 2020	BUY	$15.19 - $29.51 $75,706 - $147,077	4,984 Added 249.2%	6,984 $125,000
Q4 2018 Feb 15, 2019	BUY	$23.09 - $37.69 $46,180 - $75,380	2,000 New	2,000 $46,000

6.88M

6.2K

1.1K

Ticker HCM
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 172,955,008
Market Cap $2.5B
Description
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and rena...

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

Stay updated on Macquarie Group LTD with notifications on news.